13F HOLDINGS REPORT
Foresite Capital Management IV, LLC
Quarter ended Q2 2023 · Filed May 12, 2023 · Accession 0001104659-23-059498
Total Value
$192.7M
Positions
8
Other Managers
0
Confidential Omitted
No
Holdings (8)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Kinnate Biopharma Inc. | 49705R105 | 9,671,643 | $60.4M | 31.36% |
| 2 | Pharvaris N.V. | PHVS | 3,246,926 | $26.2M | 13.57% |
| 3 | Lyell Immunopharma, Inc. | LYEL | 10,000,000 | $23.6M | 12.25% |
| 4 | Aclaris Therapeutics, Inc. | ACRS | 2,808,034 | $22.7M | 11.79% |
| 5 | Kura Oncology, Inc. | KURA | 1,849,947 | $22.6M | 11.74% |
| 6 | Syndax Pharmaceuticals, Inc. | SNDX | 875,000 | $18.5M | 9.59% |
| 7 | Cymabay Therapeutics, Inc. | 23257D103 | 1,787,094 | $15.6M | 8.09% |
| 8 | Quantum-Si Incorporated | QSIAW | 1,771,249 | $3.1M | 1.62% |